

SCHIRMACHER, PROF. DR. PETER (M)

(*04.11.1961)



DIRECTOR

Institute of Pathology
University Hospital
Im Neuenheimer Feld 224
69120 Heidelberg

Phone: ++49/6221/56 4160

Email: peter.schirmacher@med.uni-heidelberg.de

ACADEMIC EDUCATION AND SCIENTIFIC DEGREES

1996	Habilitation (Pathology), University of Mainz
1989-1991	PhD-Study (Molecular Biology), Liver Research Center, Albert Einstein College of Medicine, New York
1987	MD-Thesis, Institute of Physiology, University of Mainz
1981-1987	Study of Medicine, University of Mainz

PROFESSIONAL CAREER

Since 2004	Professor of Pathology (C4) and Director, Institute of Pathology, Heidelberg
1998-2004	Professor of Pathology (C3), Deputy Director, Institute of Pathology, Cologne
1996	Board Certification Molecular Pathology
1995	Board Certification Pathology
1991-1998	Research Associate, Institute of Pathology, University of Mainz
1989-1991	Postdoctoral Research Fellowship (DFG); Liver Research Center, Albert Einstein College of Medicine, New York
1987-1989	Research Associate, Institute of Pathology, University of Mainz

OTHERS

Since 2015	Board member European Society of Pathology (ESP)
Since 2015	Board member National Center of Tumor Diseases (NCT)
Since 2014	Board Member German Telematics Platform (TMF)
Since 2013	Board Member International Liver Cancer Association (ILCA)
Since 2013	Chairman German Society of Pathology (DGP)
2012-2013	President German Society of Pathology (DGP)
2011-2012	President International Laennec Society of Liver Pathology
Since 2011	Board Member German Liver Foundation
Since 2011	Founder and Coordinator of the centralized BiomaterialBank Heidelberg (BMBH)
Since 2011	Principle Investigator and Coordinator of Biobanking Platforms, German Consortium for Translational Cancer Research (DKTK) and German Center for Infectious Diseases Research (DZIF)
2010-2014	Coordinator of the SFB/TR77 "Liver Cancer" (DFG)
2008-2016	Member and Speaker (2008-2012) of Section 2 (Cancer and Stem Cell Research), German Research Foundation (DFG)
2007-2009	Board Member German Association for Study of the Liver (President 2008-2009)
Since 2007	Board Member German Association of Pathology (DGP)
Since 2006	Co-Founder and Speaker of the Advisory Board 'Tissue Imaging and Analysis Center' (TIGA), Heidelberg
Since 2005	Founder and Speaker 'Tissue Bank of the National Center of Tumor Diseases'; Founder and Speaker 'Working Group Tissue Banks of the German Cancer Centers'
2004-2010	Managing board Tumorzentrum Heidelberg/Mannheim
2001-2004	Managing board 'Center for Molecular Medicine Cologne' (CMMC)

1996-1998 Managing board DFG-SFB 519
Editorial Boards: Journal of Hepatology (Associate Editor), Hepatology, Virchows Archive, Liver Cancer, Pathology Research and Practice, Pathologie

AWARDS AND APPOINTMENTS

Since 2012 Member of the German National Academy of Sciences Leopoldina
1997 Boehringer Ingelheim Award
1987 Johannes Gutenberg Award

SELECTED PUBLICATIONS

1. Mogler C, König C, Wieland M, Runge A, Besemfelder E, Komljenovic D, Longerich T, **Schirmacher P**, Augustin HG. (2017) Hepatic stellate cells limit hepatocellular carcinoma progression through the orphan receptor endosialin. *EMBO Mol Med* 9(6):741-749
2. Gdynia G, Sauer SW, Kopitz J, Fuchs D, Duglova K, Ruppert T, Miller M, Pahl J, Cerwenka A, Enders M, Mairbäurl H, Kamiński MM, Penzel R, Zhang C, Fuller JC, Wade RC, Benner A, Chang-Claude J, Brenner H, Hoffmeister M, Zentgraf H, **Schirmacher P**, Roth W. (2016) The HMGB1 protein induces a metabolic type of tumour cell death by blocking aerobic respiration. *Nat Commun* 7:10764. (Publication received the Novartis Award 2016 and the Landesforschungspreis Baden-Württemberg 2016)
3. Ploeger C, Waldburger N, Fraas A, Goepfert B, Pusch S, Breuhahn K, Wang XW, **Schirmacher P**, Roessler S (2016) Chromosome 8p tumor suppressor genes SH2D4A and SORBS3 cooperate to inhibit interleukin-6 signaling in hepatocellular carcinoma. *Hepatology* 64(3):828-42.
4. Samarin J, Laketa V, Malz M, Roessler S, Stein I, Horwitz E, Singer S, Dimou E, Cigliano A, Bissinger M, Falk CS, Chen X, Dooley S, Pikarsky E, Calvisi DF, Schultz C, **Schirmacher P**, Breuhahn K. (2016) PI3K/AKT/mTOR-dependent stabilization of oncogenic far-upstream element binding proteins in hepatocellular carcinoma cells. *Hepatology* 63(3):813-26.
5. Rudalska R, Dauch D, Longerich T, McJunkin K, Wuestefeld T, Kang TW, Hohmeyer A, Pesic M, Leibold J, von Thun A, **Schirmacher P**, Zuber J, Weiss KH, Powers S, Malek NP, Eilers M, Sipos B, Lowe SW, Geffers R, Laufer S, Zender L (2014) In vivo RNAi screening identifies mechanisms of Sorafenib resistance in liver cancer. *Nat Med* 20(10):1138-46.
6. Pellegrino R, Calvisi DF, Neumann O, Kolluru V, Wesely J, Chen X, Wang C, Wuestefeld T, Ladu S, Elgohary N, Bermejo JL, Radlwimmer B, Zörnig M, Zender L, Dombrowski F, Evert M, **Schirmacher P**, Longerich T. (2014) EEF1A2 inactivates p53 by way of PI3K/AKT/mTOR-dependent stabilization of MDM4 in hepatocellular carcinoma. *Hepatology* 59(5):1886-99.
7. Wuestefeld T, Pesic M, Rudalska R, Dauch D, Longerich T, Kang TW, Yevsa T, Heinzmann F, Hoenicke L, Hohmeyer A, Potapova A, Rittelmeier I, Jarek M, Geffers R, Scharfe M, Klawonn F, **Schirmacher P**, Malek NP, Ott M, Nordheim A, Vogel A, Manns MP, Zender L (2013) A Direct in vivo RNAi screen identifies MKK4 as a key regulator of liver regeneration. *Cell* 153(2):389-401.
8. Tschaharganeh DF, Chen X, Latzko P, Malz M, Gaida MM, Felix K, Ladu S, Singer S, Pinna F, Gretz N, Sticht C, Tomasi ML, Delogu S, Evert M, Fan B, Ribback S, Jiang L, Brozzetti S, Bergmann F, Dombrowski F, **Schirmacher P**, Calvisi DF, Breuhahn K (2013) Yes-associated protein up-regulates Jagged-1 and activates the Notch pathway in human hepatocellular carcinoma. *Gastroenterology* 144(7):1530-1542.e12.
9. Singer S, Zhao R, Barsotti AM, Ouwehand A, Fazollahi M, Coutavas E, Breuhahn K, Neumann O, Longerich T, Pusterla T, Powers MA, Giles KM, Leedman PJ, Hess J, Grunwald D, Bussemaker HJ, Singer RH, **Schirmacher P**, Prives C (2012) Nuclear pore component Nup98 is a potential tumor suppressor and regulates posttranscriptional expression of select p53 target genes. *Mol Cell* 48(5):799-810.
10. Kang TW, Yevsa T, Woller N, Hoenicke L, Wuestefeld T, Dauch D, Hohmeyer A, Gereke M, Rudalska R, Potapova A, Iken M, Vucur M, Weiss S, Heikenwalder M, Khan S, Gil J, Bruder D, Manns M, **Schirmacher P**, Tacke F, Ott M, Luedde T, Longerich T, Kubicka S, Zender L (2011) Senescence surveillance of pre-malignant hepatocytes limits liver cancer development. *Nature* 479(7374):547-51.